Ginsenoside Rg1 triggers ferroptosis to inhibit hepatocellular carcinoma via SLC7A11 downregulation Authors: Anwei Wei, Zhenzhen Liu, Fei Zhao, Yipu Zhao, Bowei Liu Published: 2026 ABSTRACT AbstractGinsenoside Rg1 (Rg1) has been reported to exert its adjunctive antitumor efficacy in cancer therapy, including hepatocellular carcinoma (HCC). Here, our study revealed the role of Rg1 on HCC involving ferroptosis. Functionally, Rg1 significantly inhibited the proliferation and migration ability of HCC cells, demonstrating its anti-HCC effect. In addition, Rg1 could induce the ferroptosis-related characteristics of HCC, thereby triggering ferroptosis. Mechanistically, SLC7A11 was identified as a potential downstream mediator of Rg1, and further studies are required to validate its functional role, and Rg1 inhibited the expression of SLC7A11. This downregulation of SLC7A11 by Rg1 recovered the ferroptosis sensitivity, thereby activating ferroptosis and contributing to HCC treatment. In conclusion, our findings unveil a link between Rg1 and ferroptosis, supporting a therapeutic strategy to overcome HCC by targeting ferroptosis.Keywords: Ginsenoside Rg1, Hepatocellular carcinoma, Ferroptosis, SLC7A11 Introduction Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide [1]. Curative therapies like resection or transplantation are only feasible for early-stage disease, yet most patients present with advanced HCC [2]. Over the last decades, the treatment paradigm has evolved from sorafenib monotherapy to a new era of systemic therapies centered on immune checkpoint inhibitors [3]. Current research is now focused on devising novel combinations and investigating effective therapeutic options [4, 5]. Ferroptosis, a newly recognized form of regulated cell death, has been shown to bypass conventional resistance mechanisms and enhance therapeutic responses in various cancers. Therefore, harnessing ferroptosis may represent a promising strategy to overcome drug resistance and improve outcomes in HCC. Ginsenoside Rg1 (Rg1), the main active component of ginseng, is characterized by its age-delaying and antioxidant functions [6]. With a history of over 2,000 years, Panax ginseng C. A. Meyer (ginseng) is a renowned medicinal plant and a perennial member of the Araliaceae family [7]. Its therapeutic use was first recorded in the ancient “Shen-Nong Herbal Classic.” Evidence suggests that Rg1 possesses anti-tumor properties against a spectrum of pathologies, including HCC [8]. In HCC pathogenesis, ferroptosis is driven by iron accumulation, which initiates lipid peroxidation and generates reactive oxygen species (ROS), ultimately resulting in plasma membrane damage and organelle dysfunction [9]. Ferroptosis plays a critical role in HCC [10]. For example, elevated FADS expression confers ferroptosis resistance and anti-PD-1 resistance by enzymatic function to stabilize PCBP2 in HCC [11]. Moreover, the potential role of ferroptosis in HCC tumor suppression and therapy remains largely unexplored [12]. In this study, our team identified a significant role of Rg1 in HCC and found that ferroptosis was involved in the tumorigenesis. Furthermore, these findings suggested that targeting ferroptosis could be a promising strategy to surmount HCC. Materials and methods Chemicals and reagents Rg1 (> 98%) was bought from AmBeed biotechn company (A100956). Rg1 was mixed with DMSO and stored at -20 ℃. Anti-SLC7A11 (No. 26864-1-AP, Proteintech, 1:1000). The Rg1 (0 µmol/L, 50 µmol/L, 100 µmol/L) was administered to HCC cells in vitro. Cell culture and treatment HCC cell lines (Huh7, MHCC97H) were provided by cell bank of Chinese Academy of Sciences. Cells were cultured in the DMEM culture medium (Gibco) with FBS (10%), streptomycin (100 mg/mL) and penicillin (100 U/mL) in incubator at 37 ℃ (5% CO2). All cell lines used in the experiments were within passages 5 to 20 and were regularly confirmed to be free of mycoplasma contamination prior to use. CCK-8 assay for half-maximal inhibitory concentration (IC50) HCC cells in the logarithmic growth phase were seeded into 96-well plates (5 × 10³ cells per well). After 24 h, the culture medium was replaced with fresh medium containing varying concentrations of Rg1, and the cells were cultured for an additional 48 h. Subsequently, CCK-8 reagent (Dojindo) was added to each well, followed by incubation for 2 h. The absorbance at 450 nm was then measured using a microplate reader. Migration assay and EdU assays HCC cell migration was assessed using a Transwell chamber assay, and the migrated cells were stained with crystal violet and counted after 24 h. Cell proliferation was evaluated with an EdU assay kit, and the proliferation rate was determined by fluorescence microscopy. Analysis of Fe2+, MDA, GSH The analysis for Fe2+, MDA, GSH levels was performed using kits according to the manufacturer’s protocol, including iron colorimetric assay kit (Applygen, E1042), Lipid Peroxidation MDA Assay Kit (Beyotime, S0131S) and GSH assay kit (Beyotime, S0053). Assessment of Intracellular ROS using DCFH-DA To assess intracellular ROS generation, Reactive Oxygen Species Assay Kit (Beyotime Biotechnology) was employed according to the instructions. HCC cells were loaded with DCFH-DA working solution (30 min, 37 °C). Imaging was captured and quantitative analysis was conducted with ImagePro Plus 6.0. Ferro-orange analysis and transmission electron microscopy (TEM) Intracellular Fe²⁺ was measured using a Ferro-orange kit per the manufacturer’s protocol. In brief, HCC cells seeded in 96-well plates (3 × 103 cells/well) were stained with 1 µM Ferro-orange in HBSS (30 min, 37 °C). Fluorescence was immediately quantified using a microplate spectrophotometer. For TEM, HCC cells treated with Rg1 were fixed with 2.5% glutaraldehyde, post-fixed with 1% osmium tetroxide, dehydrated, and embedded in epoxy resin. Ultrathin sections were stained with uranyl acetate and lead citrate, then examined under TEM. RNA-Seq RNA-Seq analysis was conducted on HCC cells treated by Rg1. Poly-A mRNA was enriched from total RNA using Oligo(dT) magnetic beads. cDNA was then synthesized, and double-stranded cDNA was purified and subjected to PCR amplification. Differential gene expression analysis was performed with DESeq, and differentially expressed genes were identified based on the criteria of |log2FoldChange| > 1 and a p-value < 0.05. Validation of molecular docking Molecular docking was performed to investigate the interaction between Rg1 and SLC7A11. The structure of Rg1 was sourced from PubChem, while the SLC7A11 crystal structure was acquired from the RCSB PDB. Following energy minimization of the ligand, docking simulations and affinity calculations were carried out with AutoDock Vina. The docking poses were finally analyzed using PyMol 2.5.2. Microscale thermophoresis (MST) assay Fluorescently labeled SLC7A11 protein was incubated with varying concentrations of Rg1. Molecular migration was monitored using an MST instrument, and the binding affinity (Kd) between Rg1 and SLC7A11 was calculated by analyzing the time-dependent changes in fluorescence intensity. Surface plasmon resonance (SPR) assay SLC7A11 protein was immobilized on a CM5 sensor chip, and solutions containing different concentrations of Rg1 were flowed over the chip surface. Resonance signal changes during the binding process were monitored in real-time, and the binding kinetics (kd) along with the equilibrium dissociation constant were determined through kinetic analysis. Animal assays in vivo BALB/c nude mice (ten 6-week-old, VitalRiver) were randomly divided into two groups. All mice received a simultaneous subcutaneous injection of HCC cells (2 × 106 cells in 100 µL PBS) into the right flank. The Rg1 group and the normal saline (NS) control group were administered via intraperitoneal injection (50 mg/kg, once a day, three days), respectively. All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of The Affiliated Cancer Hospital of Zhengzhou University. Tumor volume was calculated as length×width²/2, and tumor weight was measured. Tumor tissues were subjected to immunohistochemical (IHC) and multiplex immunohistochemical (mIHC) analyses. Statistical analysis All experimental data were analyzed with GraphPad Prism (v9.0) as mean ± SD. Prior to comparative analysis, the assumption of normality was verified for all datasets. Subsequently, student t-test was used to evaluate differences between groups. The one-way ANOVA with Tukey’s HSD was used for multiple comparisons. Statistical significance was determined at a threshold of p < 0.05. All experiments were performed with at least three independent biological replicates. Results scRNA-Seq revealed the ferroptosis-related expression profile in HCC With the rapid advancement of novel high-throughput sequencing technologies, such as single-cell sequencing, these advanced methods have been widely applied in cancer research to characterize the expression profiles of oncogenes. To explore the expression landscape of ferroptosis-related genes in HCC, we performed a reanalysis of a publicly available single-cell RNA sequencing dataset. This analysis revealed heterogeneous expression of ferroptosis-associated genes across HCC cell subpopulations, providing a rationale for investigating ferroptosis-related targets in HCC. During the validation phase of this study, we analyzed gene expression differences in hepatocellular carcinoma (HCC) using the public GEO dataset (GSE299340) (Fig. 1A). The results revealed distinct heterogeneity in transcriptional profiles among cell subpopulations within HCC tissues (Fig. 1B), with particularly notable alterations in the expression patterns of ferroptosis-related genes (Fig. 1C, D, E and F). In addition, the marker genes for each cell subpopulation are also listed (Fig. 1G). Among the ferroptosis-related genes exhibiting heterogeneous expression patterns in HCC subpopulations, SLC7A11 was notably dysregulated, prompting its further investigation as a potential target of Rg1. This finding provides potential directions for subsequent research and helps refine our research objectives. scRNA-Seq revealed the ferroptosis-related expression profile in HCC. A The public GEO dataset (GSE299340) was analyzed for the gene expression differences in hepatocellular carcinoma (HCC). B The volcano plot of subpopulation revealed the distinct heterogeneity in transcriptional profiles among cell subpopulations within HCC. C–F The ferroptosis-related genes were analyzed, including NCOA4 (C), AIFM2 (FSP1) (D), ACSL4 (E) and HMOX1 (F). The major subpopulations included epithelial cells, malignant hepatocyte. G The marker gene in multiple subpopulations Rg1 repressed the HCC tumorigenesis in vitro Ginsenoside Rg1, primarily derived from plants of the genus Panax in the Araliaceae family, was one of the most representative active components in these valuable traditional Chinese herbs and belongs to the protopanaxatriol-type saponins (Fig. 2A). Studies had indicated that Rg1 holds considerable potential as an adjunctive therapy in traditional Chinese medicine for cancer treatment, with mechanisms involving the enhancement of anti-tumor immunity and the inhibition of tumor cell proliferation. The results demonstrated a dose-dependent decrease in HCC cell viability (Fig. 2B), and the half-maximal inhibitory concentration (IC₅₀) was calculated. Further validation through Transwell (Fig. 2C and D) and EdU (Fig. 2E and F) assays confirmed that Rg1 significantly inhibited the migration and proliferation of HCC cells in a concentration-dependent manner. In conclusion, our findings indicated that Rg1 effectively suppressed HCC tumorigenesis in vitro. Rg1 repressed the HCC tumorigenesis in vitro. A The chemical structure of Rg1. (B) HCC cell lines MHCC97H and Huh-7 were treated by CCK-8. The IC50 value was calculated based on the dose-response curve. C, D Transwell assay was performed using HCC cells that treated with gradient concentration of Rg1 (0 µM, 50 µM, 100 µM). Bar scale: 30 μm. (E, F) EdU assay was performed using HCC cells that treated with gradient concentration of Rg1 (0 µM, 50 µM, 100 µM). Bar scale: 20 μm. Data are presented as mean ± SD. Comparisons among multiple groups were performed using one-way ANOVA followed by Tukey’s post-hoc test. All experiments were repeated at least three times independently (biological replicates), with n = 3 per group. *p < 0.05; **p < 0.01 Rg1 induced the ferroptosis of HCC Building on previous findings demonstrating the inhibitory effect of Rg1 on HCC, this study aimed to further elucidate the specific molecular mechanisms underlying its anti-HCC activity. Experiments related to ferroptosis revealed that Rg1 treatment significantly increased intracellular levels of Fe²⁺ (Fig. 3A), malondialdehyde (MDA) (Fig. 3B), intracellular iron ions (Fig. 3D and E), and reactive oxygen species (ROS) (Fig. 3F, G and I), while concurrently reducing glutathione (GSH) levels (Fig. 3C) and ultrastructural integrality (Fig. 3H). Collectively, these results indicated that Rg1 induced ferroptosis in HCC cells and reversed their resistance to ferroptosis. Rg1 induced the ferroptosis of HCC. A–C The levels of Fe²⁺ (A), malondialdehyde (MDA) (B), GSH (C) were tested by kits. D, E Representative confocal images (D) and quantitative analysis (E) of FerroOrange analysis in HCC cells. Scale bars: 10 μm. F, G Representative DCFH-DA staining images (F) and quantitative analysis (G) of fluorescence intensity in HCC cells. Scale bars: 10 μm. H Ultrastructure of the mitochondria in HCC cells as imaged by TEM. Scale bars: upper 2 μm, lower, 500 nm. I The lipid peroxidation (ROS) level was initially detected and quantified using flow cytometry (C11-BODIPY). Data are presented as mean ± SD. Comparisons among multiple groups were performed using one-way ANOVA followed by Tukey’s post-hoc test. All experiments were repeated at least three times independently (biological replicates), with n = 3 per group. *p < 0.05; **p < 0.01 SLC7A11 functioned as the target of Rg1 We next sought to uncover the underlying mechanisms driving the HCC ferroptosis. Using the RNA-seq, the downstream targets of Rg1 were identified (Fig. 4A and B). Enrichment pathway analysis of this dataset revealed that ferroptosis-associated pathways were significantly enriched, prompting a focused investigation into ferroptosis-related molecules (Fig. 4C). Among the factors substantially downregulated following Rg1 treatment, SLC7A11 exhibited the most pronounced reduction in expression. Molecular docking analysis demonstrated a tight binding interaction between SLC7A11 and Rg1 (Fig. 4D) with a high binding affinity (-9.1 kcal/mol) (Fig. 4E). To further validate this interaction, we performed microscale thermophoresis (MST, Fig. 4F) and surface plasmon resonance (SPR, Fig. 4G) assays. Both results consistently confirmed a strong binding interaction between Rg1 and SLC7A11. These results collectively indicated that SLC7A11 functioned as a direct target of Rg1. SLC7A11 functioned as the target of Rg1. A Heatmap, B volcano plot of RNA-seq for HCC (Huh-7) that treated with Rg1. C GSEA analysis of ferroptosis-associated pathways. D 3D binding simulation graphic of Rg1 and SLC7A11 molecular docking. E The high binding affinity (-9.1 kcal/mol) between SLC7A11 and Rg1. F MST curves of Rg1 (1 nM ~ 10 mM) to labeled SLC7A11. G SPR analysis reflected the binding within Rg1 and SLC7A11 Rg1/SLC7A11 triggered the ferroptosis of HCC Given the previously established efficacy of Rg1 in suppressing HCC progression and ferroptosis resistance, along with the identification of SLC7A11 as a downstream effector of Rg1, we sought to validate this functional relationship through subsequent cellular experiments. Multiple experimental assays demonstrated that SLC7A11 overexpression (oe-SLC7A11, Fig. 5A) reduced intracellular levels of Fe²⁺ (Fig. 5B), malondialdehyde (MDA) (Fig. 5C), reactive oxygen species (ROS) (Fig. 5E and G) and intracellular ferrous iron (Fig. 5F). In addition, SLC7A11 overexpression elevated glutathione (GSH) levels (Fig. 5D). Notably, subsequent treatment with Rg1 restored the ferroptosis-inhibitory effect associated with SLC7A11 overexpression and reversed its impact on GSH. Taken together, these data indicated that the Rg1/SLC7A11 axis triggered ferroptosis in HCC. SLC7A11 mediated Rg1-induced ferroptosis, as its overexpression significantly reversed the effects of Rg1 on ferroptosis markers. Rg1/SLC7A11 triggered the ferroptosis of HCC. A The SLC7A11 overexpression efficiency was tested by western blot. B, C, D The levels of Fe²⁺ (B), malondialdehyde (MDA) (C), GSH (D) were tested by kits. HCC (Huh-7) cells were treated with SLC7A11 overexpression (oe-SLC7A11), Rg1 (100 µM), erastin (5 µM) and Fer-1 (2 µM). E Lipid ROS was measured with C11-BODIPY 581/591 probe. Representative confocal images and quantitative analysis of F FerroOrange analysis in HCC cells. Scale bars: 10 μm. G Representative DCFH-DA staining images and quantitative analysis of fluorescence intensity in HCC cells. Scale bars: 10 μm. Student t-test was used to evaluate the difference. *p < 0.05 Rg1 impaired the progression of HCC in vivo Previous results had indicated that Rg1 inhibited the occurrence of HCC in vitro. To further confirm this finding, this project investigated the inhibitory effect of Rg1 on HCC in subsequent in vivo experiments using mice (Fig. 6A). In the mice xenograft tumor experiments, Rg1 treatment significantly suppressed the tumor volume and weight of HCC (Fig. 6B and C). Additionally, mIHC analysis revealed that Rg1 treatment significantly promoted Tunel-positive cells while inhibiting Ki67-positive cells (Fig. 6D and E). Within the tumor tissue, Rg1 treatment was able to reduce the expression level of SLC7A11 (Fig. 6F, G and H). Overall, these results collectively indicated that Rg1 impaired the progression of HCC in vivo. Rg1 impaired the progression of HCC in vivo. A BALB/c nude mice were subcutaneously injected with HCC cells, and then treated with Rg1 or NC (i.p.). B Tumor weight and C volume were tested for the tumor growth evaluation. D Tunel-positive (green) and Ki67-positive (red) cells were tested by the mIHC. E The quantitative analysis of Tunel-positive and Ki67-positive cells. F Immunofluorescence of SLC7A11 in tumor tissue. G, H IHC of SLC7A11 and Ki67 in tumor tissue. Student t-test was used to evaluate the difference. *p < 0.05 Discussion In HCC, ferroptosis is demonstrated to suppress tumor growth. The induction of ferroptosis enhances the anti-tumor efficacy of conventional therapies and represented a promising novel strategy to overcome chemotherapy resistance in HCC [13–15]. Targeting ferroptosis has emerged as a research focus in HCC treatment, primarily through inhibition of key targets such as GPX4 and SLC7A11 or utilization of agents including statins and MVD inhibitors to induce ferroptosis, thereby overcoming chemotherapy resistance and enhancing immunotherapy efficacy [16]. Although this strategy remains predominantly in basic and preclinical research stages, its unique mechanism and combination therapy potential represented a significant new direction for HCC treatment [17–20]. Ginsenoside Rg1 serves as the main active ingredient found in Panax ginseng C.A. Mey. Contemporary medicine recognizes the broad pharmacological benefits attributed to Panax ginseng C.A [21]. Mey across multiple systems, including the cardiovascular and immune systems [22]. In human cancer, the role of Rg1 is critical for tumor treatment. For example, Rg1 exerts therapeutic effects in colon cancer via associating with autophagy through the Akt/mTOR/p70S6K signaling pathway inhibition [23]. In adoptive cell therapy, Rg1-treated T cells show stronger cytotoxicity by strengthening T cell mitochondrial biosynthesis when co-cultured with tumor cells [24]. Thus, these findings highlight the role of Rg1 in cancer therapy. Here, present research findings illustrated that Rg1 significantly inhibited the proliferation and migration ability of HCC cells, which indicated its anti-HCC effect (Fig. 7). In addition, Rg1 could induce the ferroptosis-related characteristics of HCC, thereby triggering ferroptosis. Therefore, we concluded that Rg1 acted as the anti-HCC active ingredients. Currently, the inhibitory effect of Rg1 on human tumors has been confirmed in other cancers. However, research on its tumor-suppressive role in HCC remained insufficient. The findings from this study provided valuable evidence for this area. The IC50 value of Rg1 in HCC cells (approximately 90–100 µM) is comparable to that of other ferroptosis-inducing agents such as erastin and sorafenib, although the latter are more potent in certain contexts. This suggests that Rg1 may exert moderate but specific ferroptosis-inducing activity, warranting further structural optimization or combination strategies to enhance its efficacy. Ginsenoside Rg1 triggers ferroptosis to inhibit hepatocellular carcinoma via SLC7A11 downregulation For downstream targets of Rg1, RNA-Seq identified SLC7A11 as a highly promising candidate. Mechanistically, SLC7A11 was identified as a key downstream mediator of Rg1-induced ferroptosis, and Rg1 inhibited the expression of SLC7A11. This downregulation of SLC7A11 by Rg1 recovered the ferroptosis sensitivity, thereby activating ferroptosis and contributing to HCC treatment. SLC7A11 is frequently overexpressed in various tumors, including HCC. It promotes tumor cell survival, proliferation, and drug resistance by inhibiting ferroptosis, and its expression is closely associated with HCC progression and poor prognosis [25–27]. Consequently, targeting SLC7A11 has emerged as a novel therapeutic strategy to induce ferroptosis and suppress tumor growth. Collectively, our findings indicate that SLC7A11 serves as a critical downstream effector of Rg1, and its downregulation is essential for Rg1-induced ferroptosis in HCC. Targeting SLC7A11 has emerged as a promising strategy for HCC therapy, as its overexpression is associated with poor prognosis and resistance to chemotherapy and immunotherapy. However, the clinical translation of SLC7A11 inhibitors faces several challenges, including potential off-target effects, tissue-specific toxicity, and the need for predictive biomarkers to identify responsive patients. Our findings suggest that Rg1, as a natural product-derived SLC7A11 modulator, may offer a safer alternative for inducing ferroptosis in HCC, though further preclinical and clinical investigations are required to assess its translational potential. In conclusion, our findings unveil a link between Rg1 and ferroptosis. Rg1 could repress the HCC progression by inhibiting the expression of SLC7A11. These findings support a therapeutic strategy to overcome HCC by targeting ferroptosis. Acknowledgements Not applicable. Author contributions Anwei Wei, Fei Zhao, Yipu Zhao, Bowei Liu performed the assays. Anwei Wei wrote the main manuscript and prepared Figs. 1, 2, 3, 4, 5, 6 and 7. Zhenzhen Liu was responsible for the funding. All authors reviewed the manuscript. Funding This study was supported by 2019 Henan Province Medical Science and Technology Research Project (Joint Construction) (No. LHGJ20190648). Data availability The datasets generated and/or analysed during the current study are available in the Gene Expression Omnibus (GSE299340) repository, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSE299340. Declarations Ethics approval and consent to participate All animal protocol and details in present study had been conducted in accordance with the ethical principles and guidelines of the International Council for Laboratory Animal Science (ICLAS). The study had been approved by the Ethical Committee of The Affiliated Cancer Hospital of Zhengzhou University. This study did not involve human participants. Consent for publication Not applicable, as this study does not contain any identifiable human data. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Reference Associated Data Data Availability Statement The datasets generated and/or analysed during the current study are available in the Gene Expression Omnibus (GSE299340) repository, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSE299340.